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owing to the minimal optical absorption of blood and soft 
tissue in this region to allow the maximal tissue penetra-
tion. [ 5 ] When photothermal transducers accumulate in the 
tumor, they absorb NIR light and produce localized cytotoxic 
heat to ablate tumor. Obviously, biocompatible and effi cient 
NIR photothermal nanomaterials are the key component 
of NIR photothermal cancer therapy. Up to date, signifi cant 
progress has been made in the synthesis of photothermal 
agents, [ 6–15 ] such as Au nanoshells, [ 16 ] Au nanorods, [ 17 ] Au 
nanocages, [ 18 ] graphene nanosheets, [ 19 ] carbon nanotubes, [ 20 ] 
and Pd nanosheets. [ 21 ] 
 Although several plasmonic nanomaterials are subjected 
to investigation, and even Au nanoshells and nanorods have 
been explosively employed for clinical trials. [ 22–24 ] the prepa-
ration of nanomaterials that possess high photothermal effi -
ciency and effi cient renal clearance is still a great challenge. It 
is well known that the diameter of nanoparticles with effi cient 
renal clearance is required to be smaller than 10 nm, [ 25 ] which 
is the renal fi ltration limit. However, up to now, limited by the 
preparation methods or structural requirement to have effi -
cient photothermal effect in NIR, such as structural anisot-
ropy or hollow structure for plasmonic metal nanomaterials, 
 Effi cient renal clearance is of fundamentally important property of nanoparticles 
for their in vivo biomedical applications. In this work, we report the successful 
synthesis of ultra-small Pd nanosheets (SPNS) with an average diameter of 4.4 nm 
and their application in photothermal cancer therapy using a near infrared laser. 
The ultra-small Pd nanosheets have strong optical absorption in the NIR region and 
high photothermal conversion effi ciency (52.0%) at 808 nm. After being surface-
functionalized with reduced glutathione (GSH), the SPNS-GSH was administered 
to mice to investigate the biodistribution, photothermal effi cacy and tumor ablation 
in vivo. The in vivo photothermal therapy studies clearly demonstrate that surface 
modifi cation with GSH allows the nanosheets to exhibit prolonged blood circulation 
and thus high accumulation in tumors. Upon 808 nm NIR irradiation, the tumors can 
be completely ablated. More importantly, with the size below the renal fi ltration limit 
(<10 nm), the GSHylated Pd nanosheets can be nicely cleared from body through 
the renal excretion route and into urine. Together with the high effi cacy of NIR 
photothermal therapy, the unique renal clearance properties make the ultra-small Pd 
nanosheets promising for practical use in photothermal cancer therapy. 
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 1.  Introduction 
 During the past decade, nanomaterials with photothermal 
effect in near-infrared (NIR) region have attracted consid-
erable attention for their promising applications in photo-
thermal cancer therapy. [ 1–3 ] Such kind of nanomaterials are 
capable of absorbing NIR light and then effi ciently con-
verting the absorbed light into heat. [ 4 ] NIR light is highly 
desirable for in vivo imaging and therapeutic applications 
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none of the reported NIR photothermal nanomaterials meet 
such a size requirement (e.g., gold nanorods with ≈50 nm in 
length, [ 26 ] gold nanoshells with more than 100 nm in diam-
eter, [ 27 ] gold nanocages with ≈48 nm in edge length, [ 28 ] carbon 
nanotubes with 50–300 nm in lengths, [ 29 ] and graphene with 
10–50 nm in diameter [ 14 ] . Therefore, it is crucial for clinical 
application that agents administered for diagnostic or thera-
peutic purposes could be completely cleared from the human 
body within a reasonable period. The development of nano-
materials with high photothermal effi ciency and optimal 
clearance characteristics as well to minimize toxicity risks is 
highly desirable for photothermal cancer therapy. 
 In this study, we report the successful synthesis of ultra-
small Pd nanosheets (SPNS) with an average diameter of 
≈4.4 nm and their application in NIR photothermal cancer 
therapy. The SPNS not only have ultra-small size, which is 
thoroughly below the fi ltration-size threshold (10 nm), but 
also exhibit strong absorption and effi cient photothermal 
conversion of NIR light. After surface-functionalized with 
reduced glutathione (GSH), the SPNS-GSH was adminis-
tered to mice to investigate the biodistribution, photothermal 
effi cacy and tumor ablation in vivo. To comprehensively 
evaluate the performances of SPNS-GSH as a photothermal 
therapy agent in vivo, we also investigated the clearance 
characteristics and security of the particles after photo-
thermal treatments. With ultra-small size and strong absorp-
tion of light in NIR region, the SPNS exhibits great potential 
in application of photothermal therapy. 
 2.  Results and Discussion 
 In a typical synthesis of small size Pd nanosheets, 
palladium(II) acetylacetonate, poly(vinylpyrrolidone) (PVP) 
and sodium bromide were dissolved in a mixed solvent con-
sisting of water and organic solvents, such as dimethylaceta-
mide (DMAC) and  N,N -dimethylpropionamide (DMP). The 
resulting homogeneous solution was transferred to a glass 
pressure vessel. After being charged with CO to 1 bar, the 
vessel was heated from room temperature to 100 °C and 
kept at this temperature for 2 h with stirring. The resulting 
blue colloidal products were collected by centrifugation, 
and washed several times with ethanol and acetone. In 
our previous work, we reported the successful synthesis of 
plasmonic Pd nanosheets, with average size tunable from 
42 to 320 nm and thickness of 1.8 nm, using  N,N -dimeth-
ylformamide or benzyl alcohol as the solvent. The smallest 
nanosheets obtained in those systems were still too big to be 
cleaned out of body by renal. After administered into mice, 
the large sized Pd nanosheets were mainly trapped in reticu-
loendothelial system (RES; e.g. liver, spleen) and even made 
liver become dark blue. To be exerted through renal clear-
ance, the size of Pd nanosheets should be less than 10 nm. 
Fortunately, by varying the reaction solvent and mixing ratio, 
we found that the mean particle size could be controlled 
below 21 nm (diagonal length) ( Figure  1 ) while their thick-
ness was still fi xed at 1.8 nm. When DMP-water mixture was 
used as the solvent, reaction in the presence of both PVP and 
sodium bromide produced ultra-small Pd nanosheets with an 
average diameter of only ≈4.4 nm ( Figure  2 a) which is below 
the glomerular fi ltration-size threshold (10 nm) and thus par-
ticularly interesting for renal clearance studies. Noble metal 
nanostructures with such a small diameter are not expected 
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 Figure 1.  TEM images of the palladium nanosheets produced under 
different reaction conditions. (a) the Pd nanosheets with an average 
diagonal length of 20.1 nm, (b) the Pd nanosheets with an average 
diagonal length of 18.7 nm, (c) the Pd nanosheets with an average 
diagonal length of 11.1 nm, (d) Diagonal lengths of samples a–c.
 Figure 2.  Characterization and NIR photothermal properties of SPNS. 
(a) TEM image of the SPNS. Inset: diameter distribution of the SPNS. 
(b) Absorption spectrum of the SPNS. (c) Photothermal effect of 
SPNS. The temperature versus time plots was recorded for various 
concentrations of SPNS upon irradiation by a 1-W laser. (d) Micrograph 
corresponding to photothermal therapy in vitro by SPNS-PEI at an optical 
power density of 0.8 W cm −2 . Dead cells are stained with trypan blue.
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to have strong SPR absorption in the NIR region. How-
ever, due to the two dimensional sheet structures, the 4.4-nm 
small Pd nanosheets displayed well-defi ned and strong SPR 
absorption with a peak around 700 nm. The intense absorp-
tion was nicely extended into the NIR region (Figure  2 b). 
 To study the potential of using SPNS in photothermal 
therapy, the photothermal effect induced by NIR SPR 
absorption was investigated by monitoring the temperature 
changes of 1 mL aqueous solutions of various concentra-
tion of SPNS (0, 7.5, 15 and 30 ppm) irradiated by an 808 nm 
NIR laser (1 W). As shown in Figure  2 c, in marked contrast 
to pure water, the temperature of the solution containing 
30 ppm SPNS rose from 17.0 to 52.3 °C after 10 min of irra-
diation. According to Roper's method, [ 30 ] the 808 nm photo-
thermal conversion effi ciency of SPNS is as high as 52.0%, 
much higher than that of the large Pd nanosheets (LPNS) 
with edge length of 41 nm (27.6%) (see Supporting Informa-
tion, Figure S1). This suggests that the SPNS should have an 
improved performance in photothermal therapy. After sur-
face modifi ed by polyethyleneimine (PEI) to increase the 
uptake by cells, the two kinds of Pd nanosheets (i.e., SPNS 
and LPNS) were applied to photothermal ablation of cancer 
cells. In our in vitro studies, liver cancer cells were incubated 
with various Pd nanosheets (20 µg mL −1 ) for 12 h before the 
irradiation of an 808 nm laser at 0.8 W cm −2 . As illustrated in 
Figure  2 d, 100% of the cells incubated with SPNS-PEI, were 
killed after 3 min irradiation. In comparison, the same irra-
diation killed only half of the cells incubated with the LPNS-
PEI (see Supporting Information, Figure S2). 
 The high effi cacy of SPNS in vitro photothermal therapy 
motivated us to further investigate the potential of the parti-
cles in tumor ablation in vivo using NIR laser. To date, while 
signifi cant progress has been made toward the creation of the 
photothermal agents for anticancer therapy, applications of 
those nanomaterials are still severely hampered by their slow 
renal clearance and high, nonspecifi c accumulation in the 
RES after systematic administration. [ 31,32 ] It has been well-
documented that many properties of nanomaterials, such as 
particle material, size, shape, surface chemistry and charge, 
infl uence the nonspecifi c accumulation and renal clearance. 
Among those properties, both the particle size and surface 
ligands play central roles. [ 33 ] According to Zheng's research, 
GSH (a tripeptide) can not only serve as capping agent to 
render the nanoparticles with relatively low affi nities to 
serum proteins, leading to the desired stealthiness to the 
RES organs, but also contribute to effi cient renal clearance 
of small-sized nanoparticles out of body. [ 33 ] We have there-
fore modifi ed the SPNS with GSH for photothermal therapy. 
 Briefl y, 0.5 mL DMF dispersion of SPNS (5 mg mL −1 ) was 
added into 3 mL of 1.0 mg mL −1 GSH solution. The mixture 
was then shaken for 12 h at room temperature and we also 
further evaluated the dispersibility of nanoparticles in whole 
FBS by Small-angle X-ray scattering (SAXS). The pair dis-
tance distribution functions (PDDFs) were calculated from 
the fi tting of curves using the model-free method of GIFT. 
The crossover of the decay of PDDF curve with the r-axis 
refl ects the maximum dimension of the particle. The SPNS-
GSH had smaller diameter (7.5 nm) than SPNS (11.0 nm) 
in whole serum (see Supporting Information, Figure S3), 
indicating that GSHylation can effectively prevent the parti-
cles from adsorption and opsonization by serum proteins. 
 To investigate the in vivo pharmacokinetics, male 
Sprague-Dawley (SD) rats were used. Because the charac-
teristics of body clearance (CL) and renal clearance (CL R ) 
of drugs in SD rats were comparable to those in humans, 
SD rats have been hence widely chosen as the animal 
model in the study. [ 34,35 ] The SD rats weighing approxi-
mately 300 g were randomly divided into three groups (n 
= 3 per group). After a surgical operation, the cannulation 
of the jugular vein and carotid artery was performed for the 
pretreatment of rats. [ 34 ] The LPNS, SPNS and SPNS-GSH at 
a dose of 1 mg kg −1 were infused via the jugular vein to rats 
in three groups respectively. Blood sample (approximately 
0.4 mL) was drawn via the carotid artery at different time 
points after administration. Each blood sample was lysed 
by aqua regia. After dilution, the Pd ion concentrations 
of the prepared solution were measured by inductively 
coupled plasma mass (ICP-MS) spectrometry. As clearly 
revealed in  Figure  3 a, the smaller size and modifi cation by 
GSH were both helpful to prolong the circulation half-life 
of Pd nanosheets in blood. The circulation half-lives were 
remarkably increased from 0.08 h for LPNS to 1.25 h for 
SPNS-GSH. 
 It is well known that prolonged circulation facilitates 
the accumulation of nanomaterials in tumor via enhanced 
permeability and retention (EPR) effect. To further investi-
gate their biodistributions, the three kinds of Pd nanosheets 
were injected into Balb/c mice bearing 4T1 tumors via tail 
vein. Mice were sacrifi ced at 24 hours post injection (p.i.), 
and their major organs (n = 3 per group) were weighed 
and lysed by aqua regia. The obtained homogenized tissue 
lysates were diluted and measured by ICP-MS to quantita-
tively determine the Pd concentrations. Compared to LPNS, 
the smaller SPNS showed low RES uptake, consistent with 
many previous studies that RES uptake of nanomaterials is 
very size-dependent and should be higher for larger sizes. [ 31 ] 
Obviously, after GSHylation, SPNS-GSH were success-
fully avoided to be rapidly cleared out of blood and trapped 
into the RES organs. As a result, a higher tumor accumu-
lation was observed. Importantly, the total amount of Pd 
in SPNS-GSH formulation was signifi cantly low in major 
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 Figure 3.  Size and functionalization-dependent blood circulation and 
biodistribution. (a) SPNS-GSH showed prolonged blood circulation 
compared with LPNS and SPNS. (b) Biodistribution of LPNS, SPNS and 
SPNS-GSH in various organs at 24 h p.i. Samples were measured using 
ICP-MS. Error bars were based on the standard error of the mean of 
triplicate samples.
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organs, indicating that plenty of the SPNS-GSH were rapidly 
excreted from body within the fi rst 24 hours after administra-
tion (Figure  3 b). 
 Motivated by the effi cient passive targeting of SPNS-
GSH in tumors, the in vivo photothermal effect was exam-
ined using the 4T1 tumor model on Balb/c mice. The mice 
bearing 4T1 tumors were randomly divided into two groups 
(n = 5 per group) that were intravenously injected with 200 
µL of saline and SPNS-GSH in PBS (2 mg/mL), respectively. 
At 24-h p.i., the tumor was exposed to an 808 nm laser at 
the density of 1 W cm −2 for 5 min. During the irradiation, 
full-body thermographic images ( Figure  4 ) and the temper-
ature profi le (see Supporting Information, Figure S4) were 
recorded by an infrared camera. For the nanosheets-injected 
mice, the tumor surface temperature increased rapidly to 
reach 56.1 °C within 5 min, in contrast to 38.7 °C for saline-
injected mice. 
 To carry out  in vivo photothermal therapy using Pd 
nanosheets, Balb/c mice were bilaterally injected in the hind 
fl ank with ≈2×10 6 4T1 cells. After the tumor volume had 
reached about 100 mm 3 , the mice were randomly divided 
into four groups (n = 10 per group). Ten mice bearing 4T1 
tumor were injected with 200 µL of SPNS-GSH at 2 mg mL −1 . 
Another 10 mice without SPNS-GSH injection were used as 
control. At 24 h p.i., the tumor on each mouse was exposed to 
an 808 nm laser at 1 W cm −2 for 5 min. Another two control 
groups of mice with and without SPNS-GSH injection were 
not irradiated. Tumor sizes were measured every 2 days after 
treatment ( Figure  5 a). All irradiated tumors on mice injected 
with SPNS-GSH disappeared after laser irradiation, leaving 
the original tumor site with black scars which fell off in 
≈2 weeks after treatment (Figure  5 c,d). No 
tumor re-growth was noted in this treated 
group over a course of 40 days, after which 
the study was ended. In marked contrast, 
tumors in the untreated control group, the 
irradiation only group (no SPNS-GSH 
injection), and the SPNS-GSH only group 
(no laser irradiation) all showed rapid 
tumor growth, demonstrating that the NIR 
laser irradiation or SPNS-GSH injection 
by itself does not affect the tumor devel-
opment (Figure  5 a). Mice in the three con-
trol groups showed average life spans of 
≈13 days, while mice in the treated group 
were tumor-free after treatment (SPNS-
GSH injection, NIR laser irradiation) and 
survived over 40 days without a single 
death (Figure  5 b), further demonstrating 
the excellent effi cacy of SPNS-GSH for 
 in vivo cancer photothermal therapy. 
 The potential in vivo toxicity is always 
a concern for nanomaterial-based bio-
medicines. To minimize toxicity risks, an 
ideal nanomaterial-based therapy agent 
should be effectively cleared out of the 
body after treatment. The renal excre-
tion has been recognized as a desirable 
pathway for nanoparticle clearance. Con-
sidering their small size, the SPNS-GSH could be potentially 
cleared out of the body by renal way. The male SD rats were 
chosen as the animal model in the study. To confi rm that the 
SPNS-GSH can be effectively cleared from body through the 
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 Figure 4.  Photothermal effect  in vivo . Thermographic images of saline-injected (a) and 
nanosheets-injected (b) Tumor-bearing mice at different time points. 200 µL of SPNS-GSH at 
a concentration of 2,000 ppm or saline was intravenously administrated to mice. At 24 h p.i., 
the tumor was exposed to an 808 nm laser at the density of 1 W cm −2 .
 Figure 5.  Photothermal ablation of tumors in mice using intravenously 
injected SPNS-GSH. (a) Relative Tumor Volume (RTV) of different groups 
after treatment. The tumor volumes were normalized to their initial 
sizes (n = 10 per group). (b) Mortality Free Survival (MFS) curves of 
mice bearing 4T1 tumor after various treatments indicated. SPNS-GSH 
injected mice after photothermal therapy survived over 40 days without 
any single death. (c,d) Representative photographs of the mice before 
(c) and after (d) treatment. The laser irradiated tumors on SPNS-GSH 
injected mice were completely ablated.
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renal excretion route into urine, doses of 300 µg of SPNS-
GSH were intravenously administered. Urine was collected 
within a 15-day period after administration. ICP-MS was 
used to measure the Pd concentration in the urine at dif-
ferent p.i. time points. It was found that more than 6.6% of 
the SPNS-GSH were excreted out of the body within 1 day 
p.i. and up to 30.9% after 15 day p.i. ( Figure  6 a). To evaluate 
the in vivo kinetics, SD rats also were sacrifi ced at different 
time points p.i. and major organs were collected to determine 
the remained Pd by ICP-MS (Figure  6 b). As expected, SPNS-
GSH mainly accumulated in liver and spleen but could be 
cleared out from major organs over time. Meanwhile, Pd con-
tent in kidney was conversely increased. These observations 
confi rm that SPNS-GSH could be cleared out from body 
through the renal excretion route into urine. 
 Moreover, during the study, we did not notice any obvious 
sign of toxic side effects for SPNS-GSH injected mice at the 
dose of 400 µg per mouse within 40 days. Neither death nor 
signifi cant body weight drop was noted in the SPNS-GSH + 
laser treated group (see Supporting Information, Figure S5). 
Major organs of SPNS-GSH treated mice whose tumors were 
eliminated by the photothermal therapy were collected 40 
days after the treatment for histology analysis. No noticeable 
signal of organ damage was observed from haematoxylin and 
eosin (H&E) stained organ slices (see Supporting Informa-
tion, Figure S6). 
 3.  Conclusions 
 In summary, we have demonstrated the facile synthesis of 
ultra-small Pd nanosheets for effi cient in vivo photothermal 
cancer therapy. The as-prepared ultra-small Pd nanosheets 
have strong optical absorption in the NIR region and high 
photothermal conversion effi ciency (52.0%) at 808 nm. 
Surface modifi cation with GSH allows the nanosheets to 
exhibit prolonged blood circulation and high accumula-
tion in tumors. Upon 808 nm NIR irradiation, the tumors 
can be completely ablated. More importantly, with the size 
below the renal fi ltration limit (<10 nm), the GSHylated 
Pd nanosheets can be cleared from body through the renal 
excretion route and into urine. Our work suggests that ultra-
small Pd nanosheets have great potential in photothermal 
cancer therapy. 
 4.  Experimental Section 
 Synthesis of 4.4 nm Palladium Nanosheets : Pd(II) acetylaceto-
nate (Pd(acac) 2 , 10.0 mg), poly(vinylpyrrolidone) (PVP, MW = 30 
000, 32.0 mg) and NaBr (30.6 mg) were mixed together with N,N-
dimethylpropionamide (2 mL) and water (4 mL). After 10 hours on 
standing, the resulting homogeneous yellow solution was trans-
ferred to a glass pressure vessel. The vessel was then charged 
with CO to 1 bar and heated at 100 °C for 2 h before it was cooled 
to room temperature. The dark blue products were precipitated by 
acetone, separated via centrifugation and further purifi ed by an 
ethanol-acetone mixture. 
 In Vitro Photothermal Therapy : 0.5 mL solution of purifi ed Pd 
nanosheets (200 µg mL −1 ) was mixed with 0.5 mL PEI (5 mg mL −1 ). 
The mixture was kept at 4 °C overnight before centrifugation. The 
particles were then washed with water at least 5 times and then 
dispersed in 5 mL RPMI 1640 culture medium. Human hepatoma 
cells (QGY-7703) were cultured in RPMI 1640 medium in 24-well 
plates with a density of 1×10 5 cells/well. Before incubation with 
Pd nanosheets, the cells were seeded for 24 h. 0.5 mL of PEI-mod-
ifi ed Pd nanosheets in water were added to each well at a concen-
tration of 20 µg mL −1 . The incubations were carried out at 37 °C in 
5% CO 2 atmosphere for 12 h. After incubation, the cell medium 
was removed, and the cells were washed before PBS buffer solu-
tion was added. After incubation with Pd nanosheets, human 
hepatoma cells were exposed to a 0.8 W cm −2 808-nm laser for 2 
min to induce photothermal cell damage. To identify the cell via-
bility, the dead cells were stained with Trypan Blue. 
 In Vivo Photothermal Cancer Therapy : 4T1 murine breast 
cancer cells (from cell storeroom of Chinese Academy of Sci-
ence) was cultured in RPMI 1640 medium supplemented with 
10% FBS and 1% penicillin/streptomycin (all reagents from 
Hyclone) under 5% CO 2 atmosphere. The 4T1 cells (2×10 6 cells) 
were harvested, suspended in 50 µL PBS, and subcutaneously 
injected into the back of female Balb/c mice of each group (n = 
10). When the tumors were grown up to a volume of ≈100 mm 3 , 
the mice of each group were intravenously injected with 200 µL 
of each solution (2 mg mL −1 SPNS-GSH solution, PBS) and irra-
diated with 1 W cm −2 continuous NIR laser to tumor region for 
5 min after 24-h injection. The tumor size of each group was 
measured using a skinfold caliper, and tumor volume was cal-
culated using the following equation: tumor volume = ab 2 /2, 
where a is the maximum diameter of tumor and b is the min-
imum diameter of tumor. All studies on animals were done in 
accordance with the Guidelines for the Care and Use of Labora-
tory Animals in Fujian. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library 
or from the author. 
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 Figure 6.  In vivo clearance and biodistribution of SPNS-GSH. (a) 
Urinary cumulative excretion of SPNS-GSH in rats (n = 3) following i.v. 
administration at a single dose of 10 mg kg −1 . The amount of Pd in urinary 
samples were measured by ICP-MS. (b) Biodistribution of SPNS-GSH 
in different organs in mice (n = 3) within 15 days after intravenous 
injection. The percentage of the injected dose was calculated based on 
the Pd concentration measured by ICP-MS.
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